TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Tolerance of an Infant Formula Supplemented With Lactobacillus Fermentum CECT5716
Brief Summary: In the last years manipulation of intestinal microbiota with probiotics has gained an increasing interest, specially in infant nutrition since recent studies has demonstrated the presence of probiotics in human milk. However, there are few studies studying the effects of probiotics in newborns. The objective of the present study is to analyze safety and tolerance of the probiotic Lactobacillus fermentum CECT5716 isolated from human milk.


Options:
A: Arm Label: Cow's Milk; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk | Arm Label: Follow-On Formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Follow-On Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk; Assigned to Arm(s): Cow's Milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Follow-On Formula; Assigned to Arm(s): Follow-On Formula
B: Arm Label: No probiotics; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula | Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Other: Infant formula | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): No probiotics | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): Probiotic
C: Arm Label: 1 = Tested product; Type: ACTIVE_COMPARATOR; Interventions: Other: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®) | Arm Label: 2 = Control product; Type: SHAM_COMPARATOR; Interventions: Other: 2-Non fermented dairy product (control) | Intervention Type: OTHER; Name: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®); Assigned to Arm(s): 1 = Tested product | Intervention Type: OTHER; Name: 2-Non fermented dairy product (control); Assigned to Arm(s): 2 = Control product
D: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Tolerance of an Infant Formula Supplemented With Lactobacillus Fermentum CECT5716
Brief Summary: In the last years manipulation of intestinal microbiota with probiotics has gained an increasing interest, specially in infant nutrition since recent studies has demonstrated the presence of probiotics in human milk. However, there are few studies studying the effects of probiotics in newborns. The objective of the present study is to analyze safety and tolerance of the probiotic Lactobacillus fermentum CECT5716 isolated from human milk.


Options:
A: Arm Label: Probiotics; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Active 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus acidophilus NCFM | Arm Label: Active 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Combination of Lactobacillus acidophilus and Bifidobacterium lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus acidophilus NCFM; Assigned to Arm(s): Active 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Combination of Lactobacillus acidophilus and Bifidobacterium lactis; Assigned to Arm(s): Active 2
D: Arm Label: No probiotics; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula | Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Other: Infant formula | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): No probiotics | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): Probiotic

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Efficacy of Cranberry Powder in Preventing Catheter-associated Urinary Tract Infection Post Elective Gynecological Surgery
Brief Summary: Approximately 10-27% of patients undergoing gynecologic surgeries develop a catheter associated urinary tract infection (CAUTI) in the post operatory period, as bladder catheterization is a common practice in gynecologic surgery. Cranberry products provide alternative means for preventing CAUTI and could result in decreased use of antimicrobials. In this pilot study we will enroll 200 women post gynecologic surgery and randomize them to take either cranberry powder capsules or placebo powder capsules. The low risk of harm associated with using cranberry to reduce UTI coupled with its potential benefit makes it a desirable intervention for the prevention of CAUTI. The conduct/ results of this pilot /feasibility study will prepare us for the conduct of a large scale clinical trial.


Options:
A: Arm Label: Cranberry powder capsules; Type: EXPERIMENTAL; Interventions: Drug: Cranberry powder capsules | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo powder capsules | Intervention Type: DRUG; Name: Cranberry powder capsules; Assigned to Arm(s): Cranberry powder capsules | Intervention Type: DRUG; Name: Placebo powder capsules; Assigned to Arm(s): Placebo capsules
B: Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cranberry type A pro anthocyandines | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cranberry type A pro anthocyandines; Assigned to Arm(s): Cranberry | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Intervention Type: DRUG; Name: Cranberry juice cocktail; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Controlled Study for the Effect of Intravenous Lidocaine on the Tolerability of Early Oral Feeding After Laparoscopic Colorectal Surgery in Patients With Colorectal Cancer
Brief Summary: The purpose of this study is to determine whether intravenous lidocaine increase the tolerability of early oral feeding after laparoscopic colorectal surgery in patients with colorectal cancer.

* Degree of nausea/vomiting.
* Degree of postoperative pain and opioids requirement.
* Time to first flatus, time to first stool, time to tolerance of regular diet, rate of postoperative complications and duration of postoperative hospital stay.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: lidocaine | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupivacaine with hydromorphone | Intervention Type: DRUG; Name: bupivacaine with hydromorphone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: lidocaine; Assigned to Arm(s): 2
B: Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo
C: Arm Label: Lidocaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lidocaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
D: Arm Label: Intravenous lidocaine injection group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous lidocaine injection | Arm Label: Intraperitoneal lidocaine irrigation group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraperitoneal lidocaine irrigation group | Arm Label: Intravenous normal saline group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous normal saline injection | Intervention Type: DRUG; Name: Intravenous lidocaine injection; Assigned to Arm(s): Intravenous lidocaine injection group | Intervention Type: DRUG; Name: Intraperitoneal lidocaine irrigation group; Assigned to Arm(s): Intraperitoneal lidocaine irrigation group | Intervention Type: DRUG; Name: Intravenous normal saline injection; Assigned to Arm(s): Intravenous normal saline group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Trial Using a TELEmedicine Solution to Improve MEDication Adherence in Chronic Heart Failure (TELEMED-HF)
Brief Summary: TELEMED-HF is a randomized, controlled clinical intervention trial designed to: (1) examine the efficacy of an electronic Medication Adherence Support System (MASS) in improving and monitoring patients' medication adherence; to (2) i determine the effect of medication adherence on hospitalization and health care consumption.


Options:
A: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telephone behavioral education, Behavioral: Computer behavioral education | Intervention Type: BEHAVIORAL; Name: Telephone behavioral education; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Computer behavioral education; Assigned to Arm(s): Arm 1
B: Arm Label: Arm 1: PE via telemedicine; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedicine | Arm Label: Arm 2: PE in person; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: In Person | Intervention Type: BEHAVIORAL; Name: Telemedicine; Assigned to Arm(s): Arm 1: PE via telemedicine | Intervention Type: BEHAVIORAL; Name: In Person; Assigned to Arm(s): Arm 2: PE in person
C: Arm Label: TELEmonitoring intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Medication Adherence Support System (MASS) | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Medication Adherence Support System (MASS); Assigned to Arm(s): TELEmonitoring intervention
D: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TM; Type: EXPERIMENTAL; Interventions: Other: Telemonitoring | Intervention Type: OTHER; Name: Telemonitoring; Assigned to Arm(s): TM

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Danish Palliative Care Trial (DanPaCT): A Randomised Clinical Multi-centre Trial Investigating the Effect of Specialised Palliative Care on Symptoms, Survival, Economical Factors and Satisfaction in Patients With Cancer Reporting Palliative Needs
Brief Summary: Specialised palliative care (SPC) seeks to relieve suffering and improve quality of life in patients with a life threatening disease such as advanced cancer. Many patients with advanced cancer are not in contact with SPC. Previous studies have shown that among advanced cancer patients not referred to SPC there is a significant prevalence of symptoms, problems and needs. The aims of the present study are to investigate whether patients with metastatic cancer, who report palliative needs in a screening, will benefit from being referred to SPC and to investigate the economical consequences of such a referral.


Options:
A: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Early Palliative Care Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Arm Label: Conventional Cancer Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Intervention Type: BEHAVIORAL; Name: Early Palliative Care Referral; Assigned to Arm(s): Conventional Cancer Care, Early Palliative Care Referral
C: Arm Label: Standard Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Palliative Care Group | Arm Label: Integrated Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated Palliative Care Intervention | Intervention Type: OTHER; Name: Standard Palliative Care Group; Assigned to Arm(s): Standard Palliative Care Group | Intervention Type: OTHER; Name: Integrated Palliative Care Intervention; Assigned to Arm(s): Integrated Palliative Care Group
D: Arm Label: Specialised palliative care (SPC) group; Type: EXPERIMENTAL; Interventions: Other: Specialised palliative care (SPC) | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Specialised palliative care (SPC); Assigned to Arm(s): Specialised palliative care (SPC) group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Danish Palliative Care Trial (DanPaCT): A Randomised Clinical Multi-centre Trial Investigating the Effect of Specialised Palliative Care on Symptoms, Survival, Economical Factors and Satisfaction in Patients With Cancer Reporting Palliative Needs
Brief Summary: Specialised palliative care (SPC) seeks to relieve suffering and improve quality of life in patients with a life threatening disease such as advanced cancer. Many patients with advanced cancer are not in contact with SPC. Previous studies have shown that among advanced cancer patients not referred to SPC there is a significant prevalence of symptoms, problems and needs. The aims of the present study are to investigate whether patients with metastatic cancer, who report palliative needs in a screening, will benefit from being referred to SPC and to investigate the economical consequences of such a referral.


Options:
A: Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Other: early palliative care | Arm Label: early palliative care; Type: ACTIVE_COMPARATOR; Interventions: Other: early palliative care | Intervention Type: OTHER; Name: early palliative care; Assigned to Arm(s): control, early palliative care
B: Arm Label: early palliative care; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional palliative care | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard oncologic care | Intervention Type: BEHAVIORAL; Name: Interventional palliative care; Assigned to Arm(s): early palliative care | Intervention Type: BEHAVIORAL; Name: Standard oncologic care; Assigned to Arm(s): Standard care
C: Arm Label: Early palliative care consultation; Type: EXPERIMENTAL; Interventions: Other: Early palliative care consultation | Arm Label: Care as usual; Type: OTHER; Interventions: Other: Care as usual | Intervention Type: OTHER; Name: Early palliative care consultation; Assigned to Arm(s): Early palliative care consultation | Intervention Type: OTHER; Name: Care as usual; Assigned to Arm(s): Care as usual
D: Arm Label: Specialised palliative care (SPC) group; Type: EXPERIMENTAL; Interventions: Other: Specialised palliative care (SPC) | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Specialised palliative care (SPC); Assigned to Arm(s): Specialised palliative care (SPC) group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis, and Post-Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50 × 10^9/L to 100 × 10^9/L
Brief Summary: To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10\^9/L to 100 x 10\^9/L. It is anticipated that individualized dose optimization from the starting ruxolitinib level of 5 mg bid will be associated with reductions in splenomegaly, MF-associated symptoms and inflammatory cytokine levels.


Options:
A: Arm Label: Treatment (lenalidomide, prednisone); Type: EXPERIMENTAL; Interventions: Drug: lenalidomide, Drug: prednisone, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Treatment (lenalidomide, prednisone) | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Treatment (lenalidomide, prednisone) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Treatment (lenalidomide, prednisone)
B: Arm Label: Ruxolitinib 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib 5 mg
C: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib
D: Arm Label: Lenalidomide + Prednisone; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide, Drug: Prednisone | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide + Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Lenalidomide + Prednisone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This is a single-institution, prospective, randomized controlled trial. Subjects determined to need a cholecystectomy will be consented for surgery and study participation prior to enrollment in this study. Patients will then be randomized to receive either a single port laparoscopic cholecystectomy or a four port laparoscopic cholecystectomy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Laparoscopic cholecystectomy surgery | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Laparoscopic cholecystectomy surgery | Intervention Type: DEVICE; Name: Laparoscopic cholecystectomy surgery; Assigned to Arm(s): 1, 2
B: Arm Label: Single port laparoscopic device; Type: EXPERIMENTAL; Interventions: Device: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa) | Arm Label: Four-port laparoscopic device; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Four port laparoscopic cholecystectomy surgery | Intervention Type: DEVICE; Name: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa); Assigned to Arm(s): Single port laparoscopic device | Intervention Type: PROCEDURE; Name: Four port laparoscopic cholecystectomy surgery; Assigned to Arm(s): Four-port laparoscopic device
C: Arm Label: Multi port; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 4-Ports Cholecystectomy (4PC) | Arm Label: Single port; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-Port Cholecystectomy (SPC) | Intervention Type: PROCEDURE; Name: 4-Ports Cholecystectomy (4PC); Assigned to Arm(s): Multi port | Intervention Type: PROCEDURE; Name: Single-Port Cholecystectomy (SPC); Assigned to Arm(s): Single port
D: Arm Label: Standard lap chole; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard laparoscopic cholecystectomy | Arm Label: Single incision lap chole; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single incision laparoscopic cholecystectomy | Intervention Type: PROCEDURE; Name: Standard laparoscopic cholecystectomy; Assigned to Arm(s): Standard lap chole | Intervention Type: PROCEDURE; Name: Single incision laparoscopic cholecystectomy; Assigned to Arm(s): Single incision lap chole

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This is a single-institution, prospective, randomized controlled trial. Subjects determined to need a cholecystectomy will be consented for surgery and study participation prior to enrollment in this study. Patients will then be randomized to receive either a single port laparoscopic cholecystectomy or a four port laparoscopic cholecystectomy.


Options:
A: Arm Label: Single port laparoscopic device; Type: EXPERIMENTAL; Interventions: Device: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa) | Arm Label: Four-port laparoscopic device; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Four port laparoscopic cholecystectomy surgery | Intervention Type: DEVICE; Name: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa); Assigned to Arm(s): Single port laparoscopic device | Intervention Type: PROCEDURE; Name: Four port laparoscopic cholecystectomy surgery; Assigned to Arm(s): Four-port laparoscopic device
B: Arm Label: SILC; Type: EXPERIMENTAL; Interventions: Procedure: SILC | Arm Label: LC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: LC | Intervention Type: PROCEDURE; Name: SILC; Assigned to Arm(s): SILC | Intervention Type: PROCEDURE; Name: LC; Assigned to Arm(s): LC
C: Arm Label: SIL-V; Type: ACTIVE_COMPARATOR; Interventions: Procedure: single incision laparoscopic varicocelectomy | Arm Label: CTL-V; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional transperitoneal laparoscopic varicocelectomy | Intervention Type: PROCEDURE; Name: single incision laparoscopic varicocelectomy; Assigned to Arm(s): SIL-V | Intervention Type: PROCEDURE; Name: conventional transperitoneal laparoscopic varicocelectomy; Assigned to Arm(s): CTL-V
D: Arm Label: Veress needle technique; Type: OTHER; Interventions: Procedure: Laparoscopy | Arm Label: Direct trocar technique; Type: OTHER; Interventions: Procedure: Laparoscopy | Arm Label: Open technique; Type: OTHER; Interventions: Procedure: laparoscopy | Intervention Type: PROCEDURE; Name: laparoscopy; Assigned to Arm(s): Open technique | Intervention Type: PROCEDURE; Name: Laparoscopy; Assigned to Arm(s): Veress needle technique | Intervention Type: PROCEDURE; Name: Laparoscopy; Assigned to Arm(s): Direct trocar technique | Intervention Type: PROCEDURE; Name: Laparoscopy; Assigned to Arm(s): Open technique

Answer: A